We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+15.01%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$115M
AUM Growth
+$35.6M
Cap. Flow
+$33.1M
Cap. Flow %
28.7%
Top 10 Hldgs %
16.88%
Holding
267
New
23
Increased
109
Reduced
60
Closed
21

Top Buys

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$1.39M
2
INDA icon
iShares MSCI India ETF
INDA
+$872K
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$767K
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$708K
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$648K

Top Sells

Rank Stock Value
1
UPW icon
ProShares Ultra Utilities
UPW
+$1.11M
2
VDE icon
Vanguard Energy ETF
VDE
+$755K
3
RXDX
Ignyta, Inc.
RXDX
+$612K
4
FTEC icon
Fidelity MSCI Information Technology Index ETF
FTEC
+$430K
5
JUNO
Juno Therapeutics, Inc.
JUNO
+$359K

Sector Composition

Rank Sector Weight
1 Healthcare 78.8%
2 Financials 0.81%
3 Technology 0.51%
4 Consumer Discretionary 0.44%
5 Communication Services 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESPR
51
DELISTED
Esperion Therapeutics
ESPR
$936K 0.81%
12,943
+6,886
+114% +$506K
TVTX icon
52
Travere Therapeutics
TVTX
$5.33B
$935K 0.81%
41,803
-2,494
-6% -$59.4K
GBT
53
DELISTED
Global Blood Therapeutics, Inc.
GBT
$934K 0.81%
19,331
+9,941
+106% +$554K
LJPC
54
DELISTED
La Jolla Pharmaceutical Company
LJPC
$928K 0.81%
31,173
+16,779
+117% +$541K
BPMC
55
DELISTED
Blueprint Medicines
BPMC
$920K 0.8%
10,029
+5,418
+118% +$467K
SGEN
56
DELISTED
Seagen Inc. Common Stock
SGEN
$915K 0.79%
17,480
-1,023
-6% -$55.7K
IRWD icon
57
Ironwood Pharmaceuticals
IRWD
$611M
$911K 0.79%
70,463
-4,162
-6% -$51.9K
ICPT
58
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$903K 0.78%
14,681
-861
-6% -$51.9K
HALO icon
59
Halozyme
HALO
$9.72B
$898K 0.78%
45,820
-2,581
-5% -$50K
FOLD
60
DELISTED
Amicus Therapeutics
FOLD
$885K 0.77%
58,836
+31,595
+116% +$481K
SGMO
61
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$883K 0.77%
46,449
+24,858
+115% +$531K
IMMU
62
DELISTED
Immunomedics Inc
IMMU
$882K 0.77%
60,362
+32,166
+114% +$526K
RARE icon
63
Ultragenyx Pharmaceutical
RARE
$2.65B
$866K 0.75%
16,983
+9,090
+115% +$458K
KDNY
64
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$859K 0.75%
18,480
+9,933
+116% +$364K
PVLA
65
Palvella Therapeutics
PVLA
$1.98B
$857K 0.74%
1,571
+856
+120% +$530K
KYNB
66
Kyntra Bio
KYNB
$28.5M
$844K 0.73%
730
+388
+113% +$511K
BMRN icon
67
BioMarin Pharmaceuticals
BMRN
$11.5B
$836K 0.73%
10,311
-599
-5% -$51.4K
INO icon
68
Inovio Pharmaceuticals
INO
$79.8M
$823K 0.71%
14,565
+7,827
+116% +$424K
XLRN
69
DELISTED
Acceleron Pharma
XLRN
$814K 0.71%
20,821
+11,073
+114% +$471K
KERX
70
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$814K 0.71%
199,089
-11,577
-5% -$53.9K
REGN icon
71
Regeneron Pharmaceuticals
REGN
$68.8B
$810K 0.7%
2,352
-174
-7% -$60.5K
TBPH icon
72
Theravance Biopharma
TBPH
$874M
$800K 0.69%
32,989
-1,940
-6% -$53.3K
INCY icon
73
Incyte
INCY
$23.5B
$795K 0.69%
9,537
-668
-7% -$60.2K
RGNX icon
74
Regenxbio
RGNX
$623M
$793K 0.69%
26,560
+14,309
+117% +$416K
STML
75
DELISTED
Stemline Therapeutics, Inc.
STML
$791K 0.69%
51,678
+27,720
+116% +$432K
1 2
3
4 5

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q1 2018 Portfolio in Review

As of Q1 2018, Virtus ETF Advisers held 267 positions worth $115M, up 45% from $79.7M the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Virtus ETF Advisers deployed $33.1M of net new capital in Q1 2018, opening 23 new positions and adding to 109 existing holdings. Its largest new stake was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 71% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Vanguard Energy ETF, an estimated $755K trimmed.

  • Virtus ETF Advisers's largest Q1 2018 buy was Sociedad Química y Minera de Chile: 2,101 shares worth $103K.
  • Virtus ETF Advisers added most to iShares 20+ Year Treasury Bond ETF in Q1 2018, an estimated $1.39M increase.
  • Virtus ETF Advisers's biggest Q1 2018 reduction was Vanguard Energy ETF, cutting an estimated $755K.
  • Virtus ETF Advisers fully exited ProShares Ultra Utilities in Q1 2018, selling an estimated $1.11M.
  • Virtus ETF Advisers's ten largest holdings make up 17% of its $115M portfolio in Q1 2018.
  • Virtus ETF Advisers opened 23 new positions and closed 21 in Q1 2018.
  • Virtus ETF Advisers's portfolio value rose 45% quarter-over-quarter to $115M.

Based on Virtus ETF Advisers's 13F filing for Q1 2018, filed 14 May 2018.